Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $17,817 | 904 | 99.2% |
| Education | $137.94 | 5 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,277 | 160 | $0 (2024) |
| ABBVIE INC. | $2,136 | 99 | $0 (2024) |
| UCB, Inc. | $2,003 | 82 | $0 (2024) |
| Amgen Inc. | $1,262 | 58 | $0 (2024) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $1,102 | 58 | $0 (2024) |
| Celgene Corporation | $800.93 | 47 | $0 (2019) |
| Janssen Biotech, Inc. | $788.18 | 47 | $0 (2024) |
| Genentech USA, Inc. | $758.33 | 39 | $0 (2024) |
| Lilly USA, LLC | $752.15 | 34 | $0 (2024) |
| LEO Pharma Inc. | $673.71 | 49 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,692 | 123 | ABBVIE INC. ($419.90) |
| 2023 | $2,728 | 131 | UCB, Inc. ($346.41) |
| 2022 | $2,012 | 105 | Lilly USA, LLC ($269.24) |
| 2021 | $1,925 | 103 | Novartis Pharmaceuticals Corporation ($342.90) |
| 2020 | $1,685 | 76 | Amgen Inc. ($507.37) |
| 2019 | $2,828 | 129 | AbbVie, Inc. ($520.82) |
| 2018 | $1,874 | 115 | Novartis Pharmaceuticals Corporation ($322.14) |
| 2017 | $2,210 | 127 | Novartis Pharmaceuticals Corporation ($335.37) |
All Payment Transactions
909 individual payment records from CMS Open Payments — Page 1 of 37
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $19.38 | General |
| Category: Dermatology | ||||||
| 12/12/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $2.94 | General |
| Category: DERMATOLOGY | ||||||
| 12/05/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Odomzo (Drug) | Food and Beverage | In-kind items and services | $3.00 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $18.22 | General |
| Category: DERMATOLOGY | ||||||
| 11/26/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | ILUMYA (Biological) | Food and Beverage | In-kind items and services | $28.36 | General |
| Category: Dermatology | ||||||
| 11/19/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Odomzo (Drug), BLU-U | Food and Beverage | In-kind items and services | $17.18 | General |
| Category: Oncology | ||||||
| 11/18/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $20.82 | General |
| Category: IMMUNOLOGY | ||||||
| 11/12/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $17.19 | General |
| Category: Dermatology | ||||||
| 11/12/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $3.12 | General |
| Category: DERMATOLOGY | ||||||
| 11/06/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $28.49 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/06/2024 | Ortho Dermatologics, a division of Bausch Health US, LLC | SILIQ (Drug) | Food and Beverage | In-kind items and services | $22.69 | General |
| Category: Dermatology | ||||||
| 11/04/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $18.98 | General |
| Category: IMMUNOLOGY | ||||||
| 10/31/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $23.06 | General |
| Category: Dermatology | ||||||
| 10/29/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $14.76 | General |
| Category: Inflammation | ||||||
| 10/28/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $21.66 | General |
| Category: Dermatology | ||||||
| 10/22/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | ILUMYA (Biological) | Food and Beverage | In-kind items and services | $13.98 | General |
| Category: Dermatology | ||||||
| 10/22/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $2.87 | General |
| Category: Dermatology | ||||||
| 10/21/2024 | Lilly USA, LLC | EBGLYSS (Drug) | Food and Beverage | In-kind items and services | $27.55 | General |
| Category: Immunology | ||||||
| 10/16/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $43.73 | General |
| Category: Immunology | ||||||
| 10/02/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: Immunology | ||||||
| 09/25/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $16.30 | General |
| Category: Dermatology | ||||||
| 09/24/2024 | Tempus AI, Inc | Merlin Test (Device) | Food and Beverage | In-kind items and services | $15.80 | General |
| Category: Oncology | ||||||
| 09/24/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $8.62 | General |
| 09/19/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $118.00 | General |
| 09/19/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Odomzo (Drug), BLU-U | Food and Beverage | In-kind items and services | $17.51 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 2,317 | 5,205 | $1.0M | $190,285 |
| 2022 | 17 | 2,161 | 4,696 | $446,854 | $174,615 |
| 2021 | 20 | 2,246 | 4,155 | $465,311 | $180,806 |
| 2020 | 24 | 2,518 | 4,835 | $496,794 | $173,085 |
All Medicare Procedures & Services
83 procedure records from CMS Medicare Utilization — Page 2 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 320 | 2,422 | $46,018 | $11,962 | 26.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 131 | 131 | $23,973 | $9,357 | 39.0% |
| 11302 | Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2022 | 57 | 59 | $11,328 | $5,807 | 51.3% |
| 11312 | Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | Office | 2022 | 41 | 43 | $9,202 | $5,375 | 58.4% |
| 17282 | Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | Office | 2022 | 33 | 33 | $12,276 | $4,891 | 39.8% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2022 | 39 | 41 | $12,710 | $4,546 | 35.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 64 | 69 | $5,037 | $2,720 | 54.0% |
| 11311 | Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | Office | 2022 | 20 | 20 | $3,700 | $1,661 | 44.9% |
| 11307 | Shaving of skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | Office | 2022 | 16 | 16 | $3,184 | $1,529 | 48.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 16 | 16 | $2,848 | $1,152 | 40.5% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 16 | 16 | $2,912 | $1,065 | 36.6% |
| 11301 | Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | Office | 2022 | 15 | 16 | $2,560 | $933.58 | 36.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 16 | 26 | $1,300 | $261.49 | 20.1% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2022 | 19 | 77 | $231.00 | $70.06 | 30.3% |
| 17004 | Destruction of 15 or more premalignant skin growths | Office | 2021 | 413 | 500 | $170,500 | $59,696 | 35.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 646 | 842 | $98,514 | $51,891 | 52.7% |
| 17000 | Destruction of skin growth | Office | 2021 | 290 | 317 | $42,795 | $12,951 | 30.3% |
| 17282 | Destruction of malignant growth (1.1 to 2.0 centimeters) of face, ears, eyelids, nose, lips, or mouth | Office | 2021 | 64 | 65 | $24,180 | $10,046 | 41.5% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 133 | 133 | $24,339 | $9,402 | 38.6% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 261 | 1,821 | $34,599 | $8,369 | 24.2% |
| 17262 | Destruction of malignant growth (1.1 to 2.0 centimeters) of trunk, arms, or legs | Office | 2021 | 37 | 39 | $12,090 | $4,619 | 38.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 53 | 54 | $9,612 | $4,221 | 43.9% |
| 17272 | Destruction of malignant growth (1.1 to 2.0 centimeters) of scalp, neck, hands, feet, or genitals | Office | 2021 | 24 | 24 | $7,656 | $3,017 | 39.4% |
| 11104 | Punch biopsy of single skin lesion | Office | 2021 | 26 | 27 | $6,156 | $2,687 | 43.7% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 79 | 84 | $6,132 | $2,444 | 39.9% |
About Dr. Robert Albergo, MD
Dr. Robert Albergo, MD is a Dermatology healthcare provider based in Palm Harbor, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/30/2005. The National Provider Identifier (NPI) number assigned to this provider is 1063496438.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Albergo, MD has received a total of $17,955 in payments from pharmaceutical and medical device companies, with $2,692 received in 2024. These payments were reported across 909 transactions from 42 companies. The most common payment nature is "Food and Beverage" ($17,817).
As a Medicare-enrolled provider, Albergo has provided services to 9,242 Medicare beneficiaries, totaling 18,891 services with total Medicare billing of $718,791. Data is available for 4 years (2020–2023), covering 83 distinct procedure/service records.
Practice Information
- Specialty Dermatology
- Location Palm Harbor, FL
- Active Since 11/30/2005
- Last Updated 02/27/2014
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1063496438
Products in Payments
- Otezla (Drug) $1,750
- COSENTYX (Biological) $1,634
- Cimzia (Drug) $1,526
- SKYRIZI (Biological) $792.92
- Erivedge (Biological) $738.50
- TALTZ (Drug) $724.60
- Humira (Biological) $716.24
- DUPIXENT (Biological) $657.68
- COSENTYX (Drug) $543.45
- ENSTILAR (Drug) $475.88
- ILUMYA (Biological) $447.45
- OPZELURA (Drug) $411.90
- Odomzo (Drug) $402.46
- Bimzelx (Biological) $378.86
- Sotyktu (Drug) $373.96
- TREMFYA (Drug) $373.31
- VTAMA (Drug) $327.17
- RINVOQ (Biological) $316.45
- Enbrel (Biological) $312.91
- DORYX (Drug) $272.71
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.